Vascular endothelial growth factor-expressing neural stem cell for the treatment of neuropathic pain

Neuroreport. 2015 May 6;26(7):399-404. doi: 10.1097/WNR.0000000000000359.

Abstract

Previously, we determined that vascular endothelial growth factor (VEGF) improves the survival of neural stem cells (NSCs) transplanted into an ischemic environment and effectively enhances angiogenesis. Here, we applied NSCs expressing VEGF (SV-VEGF-NSCs) to treat neuropathic pain. In this study, our goal was to verify the therapeutic effect of SV-VEGF-NSCs by transplanting the cells in a sciatic nerve injury model. We compared the amount of VEGF secreted from DsRed-NSCs (control) or SV-VEGF-NSCs and observed that SV-VEGF-NSCs have a much higher expression level of VEGF. We next investigated whether transplantation with SV-VEGF-NSCs aids functional recovery and pain reduction. We confirmed that transplantation with SV-VEGF-NSCs enhances functional recovery, pain reduction, and remyelination as well as the number of blood vessels compared with the control groups. Our results show that VEGF aids functional recovery and pain reduction in a sciatic nerve injury model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Cell Survival / physiology
  • Disease Models, Animal
  • Hyperalgesia / pathology
  • Hyperalgesia / physiopathology
  • Hyperalgesia / therapy
  • Male
  • Myelin Sheath / pathology
  • Myelin Sheath / physiology
  • Neural Stem Cells / metabolism*
  • Neuralgia / pathology
  • Neuralgia / physiopathology
  • Neuralgia / therapy*
  • Pain Measurement
  • Rats, Sprague-Dawley
  • Recovery of Function / physiology
  • Sciatic Nerve / injuries
  • Stem Cell Transplantation / methods*
  • Touch
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Vascular Endothelial Growth Factor A